Tacrolimus in the treatment of chronic and refractory late-onset immune-mediated adverse effects related to silicone injections

Dermatologic Surgery

Volumn 38, Issue 1, 2012, Pages 38-47

  Alijotas Reig, Jaume ^a,b   Garcia Gimenez, Victor ^c,d   Vilardell Tarrés, Miquel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Europa Medical Centre   (Spain)

^d Spanish Society of Medicine and Cosmetic Surgery ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; BETAMETHASONE; CETIRIZINE; CORTICOSTEROID; DAPSONE; HYDROXYCHLOROQUINE; IBUPROFEN; PREDNISONE; SILICONE; TACROLIMUS;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CONFUSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; FEMALE; GINGIVA HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; INFECTION; INFLAMMATION; LIVER TOXICITY; LOW BACK PAIN; LYMPHADENOPATHY; MALE; NEPHROTOXICITY; PANNICULITIS; PRIORITY JOURNAL; PRURITUS; SILICONE PROSTHESIS; TREATMENT RESPONSE; TREMOR; VISUAL DISORDER;

ADULT; BIOCOMPATIBLE MATERIALS; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INJECTIONS; MALE; MIDDLE AGED; SILICONES; TACROLIMUS;

EID: 84855526972     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02221.x     Document Type: Article

References (41)

1. Frank PJ. Cosmetic Symposium: Restylane. The Dermatologic Society of Greater New York. Available from: http://www. dersociety.org/default.asp?id= 3&aui=sa&aid=35 Accessed February 2, 2005.
2. Engelman DE, Bradley B, Glodberg DJ. Dermal fillers: complications and informed consent. J Cosmet Laser Ther 2005;7:29-32. (Pubitemid 40896749)
3. Christensen L, Breiting V, Janssen M, Vuust J, et al. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 2005;29:34-48. (Pubitemid 40685159)
4. Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long term follow-up and review of the literature. J Eur Acad Dermatol Venereol 2008;22:150-61.
5. Alijotas-Reig J, Garcia-Gimenez V, Miró-Mur F. Delayed immune-mediated adverse effects of polyalkylimide dermal fillers. Arch Dermatol 2008;144:637-42.
6. Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M. Lateonset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology 2009;219:303-8.
7. Alijotas-Reig J. Recurrent urticarial vasculitis related to non-animal hyaluronic acid filler injection. Dermatol Surg 2009;35 (Suppl 1):395-7.
8. Andre P, Lowe NJ, Parc A, Clerici TH, et al. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther 2005;7:171-6. (Pubitemid 43111918)
9. Alijotas-Reig J, Gacia-Gimenez MI. Silicone and autoimmune diseases. An Med Interna 1998;15:276-83.
10. Duong T, Schonfeld AJ, Yungbluth M, Slotten R. Acute pneumpathy in a nonsurgical transsexual. Chest 1998;113:1127-9.
11. Villa A, Sparacio F. Severe pulmonary complications after silicone fluid injection. Am J Emerg Med 2000;18:336-7. (Pubitemid 30305293)
12. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 2000;342:781-90. (Pubitemid 30151922)
13. Bigata X, Ribera M, Bielsa I, Ferrandiz C. Adverse granulomatous reactions after cosmetic dermal silicone injections. Dermatol Surg 2001;27:198-200. (Pubitemid 32167932)
14. Kumagai Y, Shiokawa Y, Medsger TA, Rodnan GP. Clinical spectrum of connective-tissue disease after cosmetic surgery: observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum 1984;27:1-12. (Pubitemid 14176530)
15. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol 2004;3:2-15.
16. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, et al. FK-506, a novel immunossupressant isolated from a Streptomyces, I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-55. (Pubitemid 17138109)
17. Liu J, Farmer J, Lane W, Friedman J, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FK506 complexes. Cell 1991;66:807.
18. Abou-Jaoude MM, Naim R, Shaheen N, Nawfal N, et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. Transplant Proc 2005;37:3025-8. (Pubitemid 41435606)
19. Baumgart DC, Pintoff JP, Sturm A, Wiedenmann B, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a long term follow-up. Am J Gastroenterol 2006;101:1048-56. (Pubitemid 43725319)
20. Yoon KH. Eficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol 2010; 2010:686686480.
21. Prograf (Tacrolimus) Side Effects. Available from: http.//www. drugs.com Accessed January 5, 2011.
22. Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006;118(3 Suppl):77S-84S. (Pubitemid 44319093)
23. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for tissue augmentation. Aesth Plast Surg 2003;27:354-66. (Pubitemid 38365030)
24. Miró-Mur F, Hindié M, Kandhaya-Pillai R, Tobajas V, et al. Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. J Biomed Mater Res B Appl Biomater 1990;90B:510-20.
25. Ueki A, Yamaguchi M, Ueki H, Watanabe Y, et al. Polyclonal human Tcell activation by silicone in vitro. Immunology 1994;82:332-5. (Pubitemid 24241752)
26. Filion MC, Phillips NC. Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J Pharm Pharmacol 2001;53:555-61. (Pubitemid 32396548)
27. Zuckerman SH, Ahmari SE, Brya-Poole N, Evans GF, et al. Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxinemia. Inflammation 1996;20:581-97.
28. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22. (Pubitemid 29038270)
29. Desai AM, Browning J, Rosen T. Etanercept therapy for silicone granuloma. J Drugs Dermatol 2006;5:894-6.
30. Pasternack F, Fox LP, Engler D. Silicone granulomas treated with etanercept. Arch Dermatol 2005;141:13-5. (Pubitemid 40144435)
31. Rapaport MJ. Silicone granulomas treated with etanercept. Arch Dermatol 2005;141:1171. (Pubitemid 41373976)
32. Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, Curado MJ, et al. BIOGEAS Study Group. Autoimmune Rev 2010;9:188-93.
33. Williams EL, Gadola S, Edwards LJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48:716-20.
34. Dhaille F, Visseux F, Caudrom A, Dradban A, et al. Cutaneous sarcoidosis occuring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010;220:234-7.
35. James DG, Williams WJ. Sarcoidosis and other granulomatous disorders. In: Smith LLH, editor. Major problems in internal medicine. Philadelphia: W.B. Saunders Co; 1985, 24. pp. 1-254
36. Antonovic D, Callen J. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005;141:869-72. (Pubitemid 41058069)
37. Reisemberger EM, Landthaler M, Wiest I, Schröder J, et al. Foreign body granulomas caused by polymethtylmethacrylate microspheres: succesful tratment with allopurinol. Arch Dermatol 2003;139:17-20. (Pubitemid 36091569)
38. Brechtel B, Haass N, Henz BM, Kolde G. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol 1996;135:307-9. (Pubitemid 26252987)
39. Senet P, Bachelez H, Ollivaud L, Vignon-Pennamen D, et al. Minocycline for the treatment of cutaneous silicone granulomas. Br J Dermatol 1999;140:985-7. (Pubitemid 29238494)
40. Bachelez H, Senet P, Cadranel J, Kaoukhov A, et al. The use of tretraciclines for the treatment of sarcoidosis. Arch Dermatol 2001;137:69-73.
41. Hofmann S, Franke A, Fisher A, Jacobs G, et al. Genome-wide association study identifies ANX-A11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008;40:1103-6.